Dosing and administration [1]
Pluvicto®▼ (lutetium [177Lu] vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.1
Dosing and administration
Please refer to the Pluvicto Summary of Product Characteristics for full information about dosing and administration.1
Pluvicto is a ready-to-use solution. Be aware that treatment with Pluvicto contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk for cancer.1
Posology: Pluvicto is administered every 6 weeks (± 1 week) for a total of 6 doses.1
One dose of Pluvicto contains 7.4 GBq (~200 mCi) – at time of use.1
Be aware that treatment with Pluvicto contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk for cancer. Management of severe or intolerable ADRs may require temporary dose interruption (extending the dosing interval from 6 weeks up to 10 weeks), dose reduction, or permanent discontinuation of treatment with Pluvicto. Please refer to the Pluvicto SmPC for further information regarding dose reductions.
There are 3 ways to administer Pluvicto:1
- As an injection using a disposable syringe fitted with a syringe shield (with or without a syringe pump)
- As an infusion using the gravity method (with or without an infusion pump)
- As an infusion using the vial (using a peristaltic infusion pump)
For more information on the 3 administration methods, please watch the videos below.
Pluvicto®▼ (lutetium [177Lu] vipivotide tetraxetan) Prescribing Information [2]